Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management

Table 2

Subset analysis of elderly population in clinical trials of EGFR-TKIs or ALK inhibitors for NSCLC.

Study	Treatment	Age	.	HR for OS (95% CI)	HR for PFS (95% CI)
(A) EGFR-TKIs
IPASS [21]	Gefitinib	≥65	NR	NR	0.58 (0.45–0.76)
		<65	NR	NR	0.81 (0.70–0.95)
OPTIMAL [22]	Erlotinib	≥65	38	NR	0.17 (0.07–0.43)
		<65	116	NR	0.19 (0.11–0.31)
EUROTAC [23]	Erlotinib	≥65	88	NR	0.28 (0.16–0.51)
		<65	85	NR	0.44 (0.25–0.75)
LUX-Lung 3 [24, 25]	Afatinib	≥65	134	0.73 (0.43–1.21)	0.64 (0.39–1.03)
		<65	211	0.82 (0.57–1.19)	0.53 (0.36–0.76)
LUX-Lung 6 [25, 26]	Afatinib	≥65	86	0.60 (0.33–1.10)	0.16 (0.07–0.40)
		<65	278	0.87 (0.64–1.20)	0.30 (0.21–0.43)
ARCHER1050 [27]	Dacomitinib	≥65	94	NR	0.69 (0.48–0.99)
		<65	133	NR	0.51 (0.39–0.69)
AURA3 [28]	Osimertinib	≥65	177	NR	0.34 (0.23–0.50)
		<65	242	NR	0.38 (0.28–0.54)
(B) ALK inhibitors
PROFILE1014 [29]	Crizotinib	≥65	55	NR	0.90 (0.43–1.87)
		<65	288	NR	0.45 (0.29–0.70)
ALEX [30]	Alectinib	≥65	70	NR	0.45 (0.24–0.87)
		<65	233	NR	0.48 (0.34–0.70)
J-ALEX [31]	Alectinib	≥75	22	NR	0.28 (0.06–1.19)
		<75	285	NR	0.34 (0.21–0.56)

HR = hazard ratio, OS = overall survival, PFS = progression free survival, and NR = not reported.